over 50% of patients achieved 20 to 25% weight reduction thresholds at 176 weeks Semaglutide 2.4 mg: Up to 13.9% weight loss at 68 weeks Liraglutide 3.0 mg: Approximately 5.8% weight loss at 26 weeks Retatrutide (investigational triple agonist): Up to 22.1% weight loss at 48 weeks A meta-analysis of 47 randomized controlled trials confirmed a mean weight reduction of 4.57 kg, BMI reduction of 2.07 kg/m2, and waist circumference reduction of 4.55 cm versus placebo across all GLP-1 receptor agonists
All authors reviewed and approved the final manuscript
Impaired cerebral autoregulation and the other metrics of cerebral hemodynamics reported by Koch et al (rapid rise in MCA pulsatility, drop in cerebrovascular resistance index) in the immediate post-exercise period align well with the phenomenon of weightlifters blackout in which individuals may experience syncope or pre-syncope immediately following high intensity resistance exercise, particularly when in the upright standing position due to the sudden pressure drop upon release of the external load (Koch et al., 2005)
Peptides have a substantial body of clinical research behind them, and when prescribed and monitored by trained providers (like our team at Good Chemistry), they can be both effective and safe
Although cardiovascular risk has not been elevated in short-term trials, comprehensive long-term data are still pending
IGF-1 (Insulin-like Growth Factor 1) is the downstream mediator responsible for most of GHs anabolic and lipolytic effects